Viyash Scientific Reports Robust Q1 FY27 Results and European Expansion

Revenue from operations ₹9,464 Mn
Earnings After Tax ₹793 Mn

Reader Takeaway: Strong revenue and profit growth with strategic European acquisition.

What just happened

Viyash Scientific announced its financial results for the first quarter of FY27, reporting a revenue of ₹9,464 million, a significant 19.5% increase from ₹7,916 million in Q1 FY26. Earnings After Tax (EAT) saw a dramatic rise of 114.9%, reaching ₹793 million compared to ₹369 million in the same period last year. The company's EBITDA margin also improved substantially, expanding by 540 basis points to 21.6% from 16.2%.

Additionally, Viyash Scientific entered into an agreement to acquire Bio For Life in Italy, aiming to strengthen its presence in the companion animal healthcare segment and gain direct access to key European markets. The acquisition is expected to close by September 2026.

Why this matters

The strong financial performance indicates Viyash Scientific's ability to grow its top line and significantly enhance its profitability. The margin expansion suggests improved operational efficiency. The strategic acquisition in Italy signals a concerted effort to diversify and expand into high-growth international markets, specifically in the specialized companion animal healthcare sector.

The backstory

This quarter's performance follows a period where Viyash Scientific has focused on market penetration and operational synergies, likely post-integration of previous strategic moves. The company has also been working on deleveraging its balance sheet, with Net Debt standing at ₹861 million for Q1 FY27.

What changes now

The acquisition of Bio For Life, upon completion, will provide Viyash Scientific with a direct platform in the European market. This move is expected to accelerate the company's growth trajectory in the companion animal segment and diversify its geographical revenue streams.

Risks to watch

Investors should monitor potential impacts from Employee Stock Option (ESOP) costs on future profitability. Additionally, accounting adjustments related to hyperinflationary economies, such as under Ind AS 29 for markets like Turkey, may affect reported figures and require careful analysis.

Peer comparison

While specific peer data isn't provided in the filing, Viyash Scientific's reported revenue growth of 19.5% and significant profit jump suggests strong competitive positioning within its segment. Companies in the pharmaceutical and animal health sectors often see varied performance based on product pipelines and market access.

Context metrics (time-bound)

• Revenue from operations: ₹9,464 Mn (Q1 FY27)
• EBITDA: ₹2,047 Mn (Q1 FY27), Margin: 21.6%
• Earnings After Tax: ₹793 Mn (Q1 FY27)
• Net Debt: ₹861 Mn (Q1 FY27), Net Debt to LTM EBITDA: 0.1x
• Revenue YoY Growth: 19.5% (Q1 FY27 vs Q1 FY26)
• EAT YoY Growth: 114.9% (Q1 FY27 vs Q1 FY26)

What to track next

Investors should focus on the successful closure and integration of the Bio For Life acquisition. Continued margin expansion, effective management of ESOP costs, and clarity on the impact of accounting adjustments will be key indicators to watch.